


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (original) A compound of the formula I:



I

wherein:

Ar is phenyl which is unsubstituted or substituted with 1-5 of R³, wherein R³ is independently selected from the group consisting of:

- (1) halogen,
- (2) C₁-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
- (3) OC₁-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
- (4) CN, and
- (5) OH;

R¹ and R² are independently selected from the group consisting of:

- (1) hydrogen,
- (2) CN,
- (3) C₁-10alkyl, which is linear or branched and which is unsubstituted or substituted with:
 - (a) halogen, or

- (b) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R⁴, OR⁴, NHSO₂R⁴, N(C₁₋₆alkyl)SO₂R⁴, SO₂R⁴, SO₂NR⁷R⁸, NR⁷R⁸, CONR⁷R⁸, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched,
- (4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R⁴, OR⁴, NHSO₂R⁴, N(C₁₋₆alkyl)SO₂R⁴, SO₂R⁴, SO₂NR⁷R⁸, NR⁷R⁸, CONR⁷R⁸, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched,
- (5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, halogen, NO₂, CN, OH, R⁴, OR⁴, NHSO₂R⁴, N(C₁₋₆alkyl)SO₂R⁴, SO₂R⁴, SO₂NR⁷R⁸, NR⁷R⁸, CONR⁷R⁸, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched,
- (6) C₃₋₆cycloalkyl, which is optionally substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl and OC₁₋₆alkyl are linear or branched and optionally substituted with 1-5 halogens,
- (7) OH,
- (8) OR⁴, and
- (9) NR⁷R⁸;

R⁴ is C₁₋₆alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched;

R⁵, R⁶ and R⁹ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₁₀alkyl, which is linear or branched and which is unsubstituted or substituted with one or more substituents selected from:
- (a) halogen,
- (b) hydroxy,

- (c) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (d) naphthyl, wherein the naphthyl is optionally substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (e) CO₂H,
- (f) CO₂C₁₋₆alkyl,
- (g) CONR⁷R⁸,
- (3) CN,
- (4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from C₁₋₆alkyl, OC₁₋₆alkyl, hydroxy and halogen, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (5) naphthyl which is unsubstituted or substituted with 1-5 substituents independently selected from C₁₋₆alkyl, OC₁₋₆alkyl, hydroxy and halogen, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (6) CO₂H,
- (7) CO₂C₁₋₆alkyl,
- (8) CONR⁷R⁸, and
- (9) C₃₋₆cycloalkyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens;


R⁷ and R⁸ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) phenyl, which is unsubstituted or substituted with substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,

- (3) C₃₋₆cycloalkyl, which is unsubstituted or substituted with substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens, and
- (4) C₁₋₆alkyl, which is linear or branched and which is unsubstituted or substituted with:
- (a) halogen, or
 - (b) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched and optionally substituted with 1-5 halogens,
- or wherein R⁷ and R⁸ together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.


2. (original) The compound of Claim 1 of the formula Ia:



Ia

wherein Ar, R¹, R², R⁵, R⁶ and R⁹ are defined in Claim 1;
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

3. (original) The compound of Claim 1 of the formula Ib:




Ib

wherein Ar, R¹, R² and R⁵ are defined in Claim 1;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

4. (original) The compound of Claim 1 of the formula Ic:




Ic

wherein Ar, R¹ and R⁵ are defined in Claim 1;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..

5. (original) The compound of Claim 1 of the formula Id:




Id

wherein Ar and R¹ are defined in Claim 1;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..

6. (original) The compound of Claim 1 of the formula Ic:



1e

wherein Ar, R¹ and R² are defined in Claim 1;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..

7. (original) The compound of Claim 1 wherein Ar is phenyl which is unsubstituted or substituted with 1-5 of R³ which are independently selected from the group consisting of:

- (1) fluoro,
- (2) chloro,
- (3) bromo,
- (4) methyl,
- (5) CF₃, and
- (6) OH.

8. (original) The compound of Claim 1 wherein Ar is selected from the group consisting of:

- (1) phenyl,
- (2) 2-fluorophenyl,
- (3) 3,4-difluorophenyl,
- (4) 2,5-difluorophenyl, and
- (5) 2,4,5-trifluorophenyl.

9. (original) The compound of Claim 1 wherein R¹ is selected from the group consisting of:

- (1) hydrogen,

- (2) C₁₋₆alkyl, which is linear or branched and which is unsubstituted or substituted with phenyl or 1-5 fluoro,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R⁴, OR⁴, NHSO₂R⁴, N(C₁₋₆alkyl)SO₂R⁴, SO₂R⁴, SO₂NR⁷R⁸, NR⁷R⁸, CONR⁷R⁸, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched,
- (4) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, halogen, NO₂, CN, OH, R⁴, OR⁴, NHSO₂R⁴, N(C₁₋₆alkyl)SO₂R⁴, SO₂R⁴, SO₂NR⁷R⁸, NR⁷R⁸, CONR⁷R⁸, CO₂H, and CO₂C₁₋₆alkyl, wherein the C₁₋₆alkyl is linear or branched,
- (5) C₃₋₆cycloalkyl, and
- (6) NR⁷R⁸.

10. (original) The compound of Claim 1 wherein R¹ is selected from the group consisting of:

- (1) hydrogen,
- (2) CF₃,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, methyl, CF₃, OCF₃, NHSO₂Me, NHSO₂CF₃, SO₂Me, SO₂CF₃, SO₂NH₂, NH₂, NHMe, NMe₂, and CONH₂,
- (4) pyridine, pyrazine, and imidazole which is unsubstituted or substituted with 1-5 substituents independently selected from CF₃, Me, and NO₂,
- (5) cyclopropyl,
- (6) morpholine,
- (7) NH₂,
- (8) NHMe,
- (9) NMe₂, and
- (10) NHCH₂Ph.

11. (original) The compound of Claim 1 wherein R^1 is selected from the group consisting of:

- (1) hydrogen,
- (2) CF_3 ,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, methyl, CF_3 , OCF_3 , $NHSO_2Me$, SO_2Me , SO_2CF_3 , SO_2NH_2 , and $CONH_2$,
- (4) pyridine, pyrazine, or imidazole which is unsubstituted or substituted with 1-5 substituents independently selected from CF_3 , Me, and NO_2 , and
- (5) cyclopropyl.

12. (original) The compound of Claim 1 wherein R^1 is hydrogen or CF_3 .

13. (original) The compound of Claim 1 wherein R^2 is selected from the group consisting of:

- (1) hydrogen,
- (2) C_{1-6} alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 fluoro,
- (3) OH,
- (4) OR^4 , and
- (5) NR^7R^8 .

14. (original) The compound of Claim 1 wherein R^2 is selected from the group consisting of:

- (1) hydrogen,
- (2) OH,
- (3) methoxy,
- (4) isopropoxy,
- (5) CF_3 ,
- (6) NH_2 , and
- (7) $NHMe$.

15. (original) The compound of Claim 1 wherein R² is hydrogen.

16. (original) The compound of Claim 1 wherein R⁵, R⁶ and R⁹ are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) C₁₋₁₀alkyl, which is linear or branched and which is unsubstituted or substituted with one or more substituents selected from:
 - (a) halogen, and
 - (b) phenyl, wherein the phenyl is optionally substituted with 1-5 substituents independently selected from halogen, OH, C₁₋₆alkyl, and OC₁₋₆alkyl, wherein the C₁₋₆alkyl and OC₁₋₆alkyl are linear or branched and optionally substituted with 1-5 halogens.

17. (original) The compound of Claim 1 wherein R⁵, R⁶ and R⁹ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) CH₃, and
- (3) CH₂-phenyl.





18. (original) The compound of Claim 1 wherein R⁵ is H or CH₃ and R⁶ and R⁹ are hydrogen.

19. (original) A compound which is selected from the group consisting of:

Serial No.: 10/520,839

Case No.: 21139YP





Page No.: 11






Serial No.: 10/520,839

Case No.: 21139YP

Page No.: 12





or a pharmaceutically acceptable salt thereof.

20. (original) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

21-39. (cancelled)

40. (new) A method of treating Type diabetes comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Claim 1